Please assess the completion status of the following clinical trial:

Trial Title: Brexpiprazole as Adjunctive Therapy With Major Depressive Disorder and an Inadequate Response to Previous Adjunctive Therapy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Clinical diagnosis of MDD~* In current major depressive episode of ≥ 8 weeks in duration and includes an inadequate response to at least 1 adjunctive treatment.~* Positive history of at least 1 additional failure to an adequate monotherapy antidepressant treatment.~* HAM-D17 total score≥ 18~* Currently receiving SSRI of SNRI with adjunctive treatment for at least 6 weeks before screening.~* Willing to discontinue use of all prohibited psychotropic medications~* Historical positive serological results for HIV, hepatitis B/C~* Able to provide written informed consent prior to the initiation of any protocol-required procedures~* Subjects who could potentially benefit from adjunctive treatment with Brexpiprazole~Exclusion Criteria:~* Sexually active women of childbearing potential~* Male subjects not practicing 2 different methods of birth control~* Females who are breastfeeding and/or who have a positive pregnancy test result~* Subjects who have received ECT for the current major depressive episode.~* Subjects who have had an inadequate response to ECT~* Current need for involuntary commitment or who have been hospitalized within 4 weeks of screening~* Current Axis I (DSM-IV-TR)~* Current Axis II (DSM-IV-TR)~* Subjects experiencing hallucinations, delusions, or any psychotic symptomatology in the current major depressive episode.~* Subjects receiving new onset psychotherapy.~* Subjects who answer Yes on the C-SSRS Suicidal Ideation Item 4, Item 5, or on any of the 5 C-SSRS Suicidal Behavior Items~* Subjects who have met DSM-IV-TR criteria for substance abuse or dependence within the past 180 days~* Hypothyroidism or hyperthyroidism~* Clinically significant neurological, hepatic, renal, metabolic, haematological, immunological, cardiovascular, pulmonary, or gastrointestinal disorders~* Currently treated with insulin for diabetes~* Uncontrolled hypertension or symptomatic hypotension, or orthostatic hypotension~* Known ischemic heart disease or history of myocardial infarction, congestive heart failure, angioplasty, stenting, or coronary artery bypass surgery~* Epilepsy or history of seizures~* Positive drug screen~* The following laboratory test and ECG results are exclusionary:~  1. Platelets ≤ 75,000/mm3~ 2. Hemoglobin ≤ 9 g/dL~ 3. Neutrophils, absolute ≤ 1000/mm3~ 4. AST \> 2 × ULN~ 5. ALT \> 2 × ULN~ 6. CPK \> 3 × ULN, unless discussed with and approved by the medical monitor~ 7. Creatinine ≥ 2 mg/dL~ 8. HbA1c ≥ 7.0%~ 9. Abnormal free T4 (Note: Free T4 is measured only if result for TSH is abnormal.)~ 10. QTcF ≥ 470 msec for females and ≥ 450 msec for males~* Treatment with an MAOI or EMSAM within 14 days of the Baseline visit.~* Use of benzodiazepines and/or hypnotics within 7 days prior to the first dose of IMP~* Use of oral neuroleptics within 7 days prior or long-acting approved atypical antipsychotics ≤ 1 full cycle plus ½ cycle prior to the first dose of IMP~* Subjects who would be likely to require prohibited concomitant therapy during the trial.~* Subjects who previously participated in any prior brexpiprazole trial~* History of neuroleptic malignant syndrome or serotonin syndrome~* History of true allergic response to more than one class of medications~* Prisoners or subjects who are compulsorily detained for treatment of either a psychiatric or physical illness.~* Subjects who participated in a clinical trial within the last 180 days or who participated in more than 2 clinical trials within the past year.~* Any subject who, in the opinion of the investigator or medical monitor, should not participate.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- ADT and Brexpiprazole (Type: EXPERIMENTAL): ADT and Brexpiprazole

Based on this trial design, predict the completion outcome and termination type (if applicable).